World of DTC Marketing

FEBRUARY 1, 2022

According to STAT News “after a double-digit decline in 2021, the sector has fallen another 20% in the new year, erasing billions in value and leading even the most seasoned investors to question whether biotech has further to fall. Can small biotech companies survive? Many large pharmaceutical companies reported record performances in 2021, whether that’s a decade-high stock price or shares that outperformed the broader market as investors continued to pour money into companies maki

Food and Drug Administration 234

Food and Drug Administration FDA Pharmaceutical Food 234

Prognos Health

FEBRUARY 1, 2022

Wall Street expectations and enthusiasm have been high surrounding the biotechnology and pharmaceutical sectors in recent years with investors eager to profit from the next big blockbuster therapies. However, a recent report from L.E.K. Consulting shows a considerable percentage of new drug launches have underperformed initial estimates.

Consulting 52

Consulting Pharmaceutical 52

Tribeca Knowledge

FEBRUARY 1, 2022

I n our new report Launch Readiness 2022 , we consider how launch strategists may best navigate a fast-changing yet still commercially ripe environment for pharmaceutical launch readiness. We show how digital transformation and cutting-edge launch management software help companies track the status of launch activities and manage global launch challenges, in real-time and across both functions and countries.

Management 52

Management Pharmaceutical Pharma 52

Prognos Health

FEBRUARY 1, 2022

Wall Street expectations and enthusiasm have been high surrounding the biotechnology and pharmaceutical sectors in recent years with investors eager to profit from the next big blockbuster therapies. However, a recent report from L.E.K. Consulting shows a considerable percentage of new drug launches have underperformed initial estimates. According to the report: Nearly half the drugs launched in the past 15 years underperformed analyst estimates by more than 20% Only one-fifth of new medications

Consulting 52

Consulting Physicians Biopharma Pharma 52

Advertisement

Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud

Distribution

Star OUTiCO

FEBRUARY 1, 2022

Joanne Irving, Head of Market Access and Service Redesign, Star OUTiCO. My career started as an RGN, and I continue to work in the NHS in renal medicine. I’ve worked in the pharmaceutical industry full-time for 24 years across a variety of roles but mostly within Leadership and Market Access, and latterly heading up Key Account Management at Boehringer-Ingelheim.

Key account management 52

Key account management Medicine Marketing Management 52

Clarivate

FEBRUARY 1, 2022

In the rush to close M&A transactions, organizations can risk loss of IP value or even IP rights. Read to find out more about these IP risks. Global merger and acquisition (M&A) activity set new records in 2021, as volumes reached $5.8 trillion—a 64% increase over the previous year. [1] While M&A transactions have become a cornerstone of corporate growth strategies, they can be disruptive to the intellectual property (IP) portfolios of the companies involved.

Management 52

Management Leads Specialization Professional Services 52